Log in Register
Menu

MCF7/S0.5 Cell Line

Invented by Dr Anne Lykkesfeldt at Danish Cancer Society

Info

Catalogue Number 152090
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line MCF7
Host Human
Tissue Breast
Disease Keywords Breast cancer
Model Tumour line
Relevance The MCF7/S0.5 cell line has been established to grow at low serum. The presence of hormones in the serum required in tissue culture media complicates the demonstration of specific hormone and antihormone effects. Methods to overcome this have included charcoal-treated serum and serum-free medium. However, both methods have serious drawbacks. Therefore, the MCF-7/S0.5 cell line has been adapted to long-term growth at 0.5 % fetal bovine serum in order to reduce the oestrogen supply via serum and to enable oestrogen receptor-mediated growth inhibition with the antiestrogen tamoxifen.

The MCF7/S0.5 cells are also useful for studies of effect of oestrogens, if they, instead of 1 % fetal calf serum, are cultivated with 10% newborn calf serum which contains very low oestrogenic activity.
Production Details This MCF7 subline was established buy stepwise reduction in the serum concentration from 5% fetal calf serum to 0.5 % in growth medium consisting of DMEM: Ham's F-12 medium (1:1) supplemented with 2mM glutamine and insulin (6ng/ml). MCF7/S0.5 express both oestrogen receptor and progesterone receptor.
Research Area Cancer, Drug Discovery & Development
Growth/Phenotype Keywords Adapted to growth in low serum concentrations
Recommended Growing Conditions Phenol-red-free DMEM/F12 medium supplemented with 1% fetal calf serum 2.5 mM Glutamax and 6 ng/ ml insulin,
Notes Passage 408 (AL2542, AL2543)

Grows in low serum
Cellosaurus ID CVCL_1D47

References: 10 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418.

Thomsen et al. 2015. Breast Cancer Res Treat. :. PMID: 26585578.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Sonne-Hansen et al. 2005. J Steroid Biochem Mol Biol. 93(1):25-34. PMID: 15748829.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264.

Lykkesfeldt et al. 1989. Mol Cell Endocrinol. 62(2):287-96. PMID: 2744230.

Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513.

Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856.


Add a reference

References: 10 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418.

Thomsen et al. 2015. Breast Cancer Res Treat. :. PMID: 26585578.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Sonne-Hansen et al. 2005. J Steroid Biochem Mol Biol. 93(1):25-34. PMID: 15748829.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264.

Lykkesfeldt et al. 1989. Mol Cell Endocrinol. 62(2):287-96. PMID: 2744230.

Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513.

Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856.


Add a reference

References: 10 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418.

Thomsen et al. 2015. Breast Cancer Res Treat. :. PMID: 26585578.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Sonne-Hansen et al. 2005. J Steroid Biochem Mol Biol. 93(1):25-34. PMID: 15748829.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264.

Lykkesfeldt et al. 1989. Mol Cell Endocrinol. 62(2):287-96. PMID: 2744230.

Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513.

Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856.


Add a reference


This reagent does not have any reviews at the moment.